

Special Issue

New Insights into the Molecular Mechanism of Epithelial Plasticity in Cancer

Message from the Guest Editor

Epithelial cell plasticity is a reversible program that refers to the ability of epithelial cells to dynamically switch between different phenotypic cellular states. This program has been highlighted during the epithelial-to-mesenchymal transition (EMT) in tumour progression and metastasis. Tumour cells undergo EMT loose cell-cell and cell-extracellular matrix interactions, leading to cell migration and invasion. It has become evident that transcriptional, post-transcriptional, and post-translational events are critical regulators of the EMT. Moreover, in recent years, EMT has been associated to stemness and therapy resistance, critically representing one of the major challenges in oncology. Indeed, EMT has been proposed as a good therapeutic target for the designing of novel strategies against cancer. In this Special Issue, we focus on new molecular mechanisms implicated by the epithelial plasticity in cancer and novel therapeutic strategies against EMT to overcome drug resistance and metastasis.

Guest Editor

Dr. Angélica Figueroa

Epithelial Plasticity and Metastasis Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), 15006 A Coruña, Spain

Deadline for manuscript submissions

closed (16 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/51570

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)